RCC
Oncology · 2006–2024
42decisions
14medicines
17carried consumer input
37individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| bevacizumab Metastatic colorectal cancer, locally recurrent or metastatic breast cancer, advanced/metastatic/recurrent non-squamous non-small cell lung cancer, advanced… | Mar 2024 | Recommended with restriction | 1 individuals |
| cabozantinib Treatment of advanced renal cell carcinoma (RCC) in treatment-naïve adults with intermediate or poor risk and in adults following prior treatment with a… | Mar 2024 | Recommended | input received ANZUP Cancer Trials Group · Rare Cancers Australia · Medical Oncology Group |
| cabozantinib Stage IV clear cell variant renal cell carcinoma (RCC) in patients who are classified as intermediate or poor risk according to the International Metastatic… | Mar 2024 | Recommended | input received Rare Cancers Australia · Medical Oncology Group |
| pembrolizumab Adjuvant treatment of patients with renal cell carcinoma (RCC) with clear cell component who are at intermediate-high or high risk of recurrence following… | Nov 2024 | Recommended | 4 individuals Rare Cancers Australia |
| pembrolizumab First-line treatment of advanced (Stage IV) clear cell variant renal cell carcinoma in patients classified as intermediate or poor risk according to IMDC… | Mar 2022 | Recommended with restriction | input received Medical Oncology Group |
| avelumab First-line treatment of advanced (stage IV) clear cell variant renal cell carcinoma in patients classified as intermediate or poor risk according to IMDC… | Mar 2021 | Recommended | unclear |
| avelumab First-line treatment of advanced (stage IV) clear cell variant renal cell carcinoma in patients with intermediate to poor prognostic risk according to IMDC… | Mar 2020 | Not recommended | input received Rare Cancers Australia |
| cabozantinib Stage IV clear cell variant advanced renal cell carcinoma (RCC) with intermediate to poor risk classification according to IMDC criteria, in patients who have… | Mar 2020 | Not recommended | input received Rare Cancers Australia · Medical Oncology Group |
| cabozantinib Stage IV clear cell variant advanced renal cell carcinoma (RCC) with intermediate to poor risk classification according to IMDC criteria in treatment-naïve… | Nov 2020 | Recommended with restriction | input received Medical Oncology Group |
| cabozantinib First-line treatment of Stage IV clear cell variant renal cell carcinoma (RCC) in patients meeting IMDC criteria for intermediate to poor risk disease. | Mar 2019 | Not recommended | unclear |
| nivolumab + ipilimumab First-line treatment of Stage IV clear cell variant renal cell carcinoma (RCC) in patients with intermediate to poor risk disease according to IMDC criteria… | Jul 2018 | Not recommended | 7 individuals |
| lenvatinib Stage IV clear cell variant renal cell carcinoma (RCC) in patients who have progressed after first-line treatment with a tyrosine kinase inhibitor, for use in… | Mar 2018 | Not recommended | none received |
| nivolumab First-line treatment of Stage IV clear cell variant renal cell carcinoma in patients meeting IMDC intermediate to poor risk group criteria. | Nov 2018 | Recommended with restriction | input received |
| nivolumab Stage IV clear cell variant renal cell carcinoma (RCC) in patients who have progressed according to RECIST following first-line treatment with a… | Mar 2017 | Recommended with restriction | 4 individuals |
| cabozantinib Treatment of patients with Stage IV (unresectable) clear cell variant renal cell carcinoma (RCC) with progressive disease following first-line treatment with a… | Dec 2017 | Recommended | 1 individuals |
| lenvatinib Treatment of patients with stage IV clear cell variant renal cell carcinoma (RCC) whose disease has progressed following first-line tyrosine kinase inhibitor… | Nov 2017 | Not recommended | none received |
| nivolumab Advanced or metastatic clear cell variant renal cell carcinoma (RCC) in patients who have progressed following first-line treatment with a tyrosine-kinase… | Jul 2016 | Not recommended | 1 individuals |
| nivolumab Second-line treatment of Stage IV clear cell variant renal cell carcinoma (RCC) in patients with progressive disease following first-line tyrosine kinase… | Nov 2016 | Not recommended | 7 individuals |
| everolimus Stage IV clear cell variant renal cell carcinoma (RCC) after disease progression following first-line treatment with a tyrosine kinase inhibitor. | Mar 2014 | Recommended with restriction | 2 individuals |
| axitinib Second-line treatment of stage IV clear cell variant renal cell carcinoma (RCC) in patients with progressive disease following first-line tyrosine kinase… | Nov 2014 | Recommended with restriction | 6 individuals |
| sorafenib Second-line treatment of stage IV clear cell variant renal cell carcinoma (advanced RCC) in patients who have failed first-line treatment with a tyrosine… | Nov 2014 | Recommended | 4 individuals |
| axitinib Second-line treatment of Stage IV clear cell variant renal cell carcinoma in patients with WHO performance status of 2 or less where disease progression has… | Nov 2013 | Not recommended | no section in document |
| sorafenib Stage IV (advanced) clear cell variant renal cell carcinoma as second-line treatment in patients who have failed first-line therapy with sunitinib or pazopanib… | Nov 2013 | Not recommended | unclear |
| pazopanib Initial and continuing treatment as the sole PBS-subsidised tyrosine kinase inhibitor therapy for stage IV clear cell variant renal cell carcinoma (RCC) in a… | Mar 2012 | Recommended with restriction | no section in document |
| pazopanib Initial and continuing treatment of stage IV clear cell variant renal cell carcinoma (RCC) in newly diagnosed patients meeting MSKCC low to intermediate risk… | Mar 2012 | Recommended with restriction | no section in document |
| sorafenib initial and continuing treatment of Stage IV clear cell renal carcinoma in a patient who has failed therapy with first line treatment and meets certain… | Nov 2012 | Recommended | no section in document |
| sorafenib Initial and continuing treatment of Stage IV clear cell renal carcinoma in patients who have failed first-line therapy with favourable or intermediate MSKCC… | Nov 2012 | Recommended | no section in document |
| everolimus initial and continuing treatment of Stage IV clear cell variant renal cell carcinoma in a patient with a WHO status of 2 or less, who has failed treatment with… | Nov 2011 | Not recommended | unclear |
| everolimus Initial and continuing treatment of Stage IV clear cell variant renal cell carcinoma in patients with WHO status 2 or less who have failed treatment with… | Nov 2011 | Not recommended | unclear |
| everolimus Initial and continuing treatment of Stage IV clear cell variant renal cell carcinoma in a patient with a WHO status of 2 or less who has progressive disease on… | Jul 2010 | Not recommended | no section in document |
| pazopanib treatment of stage IV advanced and/or metastatic, clear cell variant, renal cell carcinoma (RCC) in an adult patient who meets certain criteria | Jul 2010 | Not recommended | no section in document |
| everolimus Initial and continuing treatment of Stage IV clear cell variant renal cell carcinoma in patients with WHO status ≤2 who have progressive disease on sunitinib… | Jul 2010 | Not recommended | no section in document |
| pazopanib Treatment of stage IV advanced and/or metastatic, clear cell variant renal cell carcinoma (RCC) in adult patients who meet certain criteria. | Jul 2010 | Not recommended | no section in document |
| everolimus Treatment of patients with Stage IV clear cell variant renal cell carcinoma after failure of treatment with sorafenib or sunitinib. | Nov 2009 | Not recommended | no section in document |
| sunitinib malate treatment of advanced (unresectable or metastatic) renal cell carcinoma (RCC) in patients with an ECOG performance status of 0 or 1 | Jul 2008 | Recommended with restriction | no section in document |
| temsirolimus treatment of advanced renal cell carcinoma (RCC) in patients with a poor prognosis who meet certain criteria | Jul 2008 | Recommended | no section in document |
| sorafenib tosylate Initial and continuing treatment of advanced renal cell carcinoma in patients with WHO performance status 2 or less, with continuing treatment defined as… | Mar 2008 | Not recommended | no section in document |
| sunitinib malate Treatment of advanced (unresectable or metastatic) renal cell carcinoma (RCC) in patients with an Eastern Cooperative Oncology Group (ECOG) performance status… | Mar 2008 | Not recommended | no section in document |
| sunitinib malate treatment of advanced renal cell carcinoma (RCC) | Mar 2007 | Deferred | no section in document |
| sunitinib malate Treatment of advanced renal cell carcinoma (RCC) as first-line therapy. | Mar 2007 | Deferred | no section in document |
| sorafenib initial and continuing treatment of advanced renal cell carcinoma in patients with WHO performance status of 2 or less, and beyond 3 months for those with… | Nov 2006 | Recommended | no section in document |
| sorafenib tosylate Initial and continuing treatment of advanced (unresectable or metastatic) renal cell carcinoma in patients with WHO performance status of 2 or less. | Nov 2006 | Recommended | no section in document |
Who spoke
Rare Cancers Australia · Medical Oncology Group · ANZUP Cancer Trials Group
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 17 of 21 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.